Remdesivir - A Drug in Search of a Diseases? Review Of Highly Biased Study to Oversell a Drug

Author(s): Alexis Lacout, Xavier Azalbert, Corinne Reverbel, Jean-François Lesgards, Dominique Cerdan, Gérard Guillaume, Martin Zizi, Christian Perronne

The pharmaceutical industry regularly uses highly biased, unreliable studies to oversell their drugs. In recent years, a growing number of scientific publications studying innovative pharmaceutical products have included studies with such significant biases as to invalidate the results promoted by the authors. Remdesivir caught our attention because, despite the mediocre results obtained in randomized clinical trials for the treatment of Covid-19, new studies are attempting to find an interest in the use of the molecule. Recently, we read with interest the study by Mozaffari et al. published in Clinical Infectious Disease, which claims to show a reduction in mortality with remdesivir used at the start of hospitalization for a few days. Methodologically the study presents multiple biases, the use of this drug is not relevant due to its lack of efficacy and its toxicity and because most cases are benign, and the groups studied are in no way reliably comparable. We think it's high time scientists spoke out against this bad medical science, which has led to poor patient care.